# COSELA

NDC: 73462-101
Generic name: trilaciclib
Labeler / Manufacturer: G1 Therapeutics, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 20210212
Marketing ended: 20281231
FDA application: NDA214200

## Active ingredients

- TRILACICLIB DIHYDROCHLORIDE: 300 mg/20mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"73462-101"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=73462-101
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b06922c-498d-4871-a037-84a44e6a6b6c